Taro Pharmaceutical (TARO)

Add to Watchlists
Create an Alert
101.26 -0.25  -0.25% NYSE Apr 25, 20:00 Delayed 2m USD

Taro Pharmaceutical Income Statement (Quarterly)

Export Data

December 2017 - September 2015

Previous Periods

Income (Quarterly) 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12 2015-09
Operating Revenue Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Revenue 155.46M 169.91M 161.32M 196.41M 220.40M 228.79M 233.78M 265.07M 258.34M 212.06M
Cost of Goods Sold Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Gross Profit 102.92M 125.12M 116.54M 143.83M 167.34M 177.29M 182.79M 224.23M 214.18M 168.76M
SG&A Expense 21.83M 18.34M 24.25M 22.21M 20.31M 20.89M 22.25M 22.56M 22.87M 24.05M
Research and Development Expense 17.46M 18.00M 14.66M 19.88M 18.00M 14.85M 17.92M 19.95M 17.94M 18.73M
Special Income and Charges Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Total Operating Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Operating Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Non-Operating Interest Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Non-Operating Interest Income Expense Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Other Income and Expenses Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Interest Income 4.962M -27.98M 4.476M 23.82M 3.961M 16.92M 3.306M 9.964M 3.038M 3.401M
Pre-Tax Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Provision for Income Taxes Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Extraordinary Items, Income Statement Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Income Attributable to Minority Interest Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Net Income 17.97M 52.39M 54.50M 82.99M 139.82M 123.66M 109.90M 114.95M 189.00M 133.35M
Normalized Income Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBITDA Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Reconciled Depreciation Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EBIT Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Basic EPS (Quarterly) 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12 2015-09
EPS Basic from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic from Tax Loss Carryforward Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Basic EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Basic Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Diluted EPS (Quarterly) 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12 2015-09
EPS Diluted from Continuing Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Discontinued Operations Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Extraordinaries Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted from Tax Loss Carryforward Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Normalized Diluted EPS Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
EPS Diluted 0.4500 1.300 1.350 2.060 3.420 3.000 2.590 2.670 4.410 3.110
Shares Data (Quarterly) 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12 2015-09
Average Basic Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
Average Diluted Shares Outstanding Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade Upgrade
SEC Filing Links 2017-12 2017-09 2017-06 2017-03 2016-12 2016-09 2016-06 2016-03 2015-12 2015-09
As Originally Reported AOR AOR AOR AOR AOR AOR AOR AOR AOR AOR
Restated Restated Restated Restated Restated Restated Restated

December 2017 - September 2015

Previous Periods

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.